{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:35:55Z","timestamp":1793756155928,"version":"4.6.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10,1]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>The emergence of 3q26.2 rearrangements in CML is associated with resistance to TKI treatment and poor prognosis. 3q26.2 rearrangements play a predominant role in determining prognosis, irrelevant to the presence or absence of other additional chromosomal abnormalities in CML.<\/jats:p>","DOI":"10.1182\/blood-2015-05-646489","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T02:20:29Z","timestamp":1438741229000},"page":"1699-1706","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":64,"title":["Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors"],"prefix":"10.1182","volume":"126","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematopathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Beaty","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wake Forest Baptist Health, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ai","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham M.","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Young","family":"Ok","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematopathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4944","key":"2019111904041867400_B1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"5405","key":"2019111904041867400_B2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"26","key":"2019111904041867400_B3","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111904041867400_B4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis.","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111904041867400_B5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/leu.2009.222","article-title":"Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.","volume":"24","author":"Haferlach","year":"2010","journal-title":"Leukemia"},{"issue":"7","key":"2019111904041867400_B6","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation.","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111904041867400_B7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11899-013-0194-x","article-title":"Genetic events other than BCR-ABL1.","volume":"9","author":"Neviani","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"2019111904041867400_B8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"2019111904041867400_B9","first-page":"179","article-title":"Chronic myeloid leukemia.","volume-title":"Cancer Cytogenetics","author":"Fioretos","year":"2009"},{"issue":"6","key":"2019111904041867400_B10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111904041867400_B11","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2019111904041867400_B12","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.1998.16.10.3279","article-title":"Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.","volume":"16","author":"Cortes","year":"1998","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111904041867400_B13","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.","volume":"116","author":"Verma","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"2019111904041867400_B14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","article-title":"The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.","volume":"100","author":"O\u2019Dwyer","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111904041867400_B15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2019111904041867400_B16","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.","volume":"28","author":"Lugthart","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111904041867400_B17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111904041867400_B18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/leu.2011.5","article-title":"The inv(3)(q21q26)\/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML.","volume":"25","author":"Haferlach","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"2019111904041867400_B19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2013.096420","article-title":"Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)\/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.","volume":"99","author":"Rogers","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2019111904041867400_B20","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes.","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111904041867400_B21","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.V76.12.2594.2594","article-title":"t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia.","volume":"76","author":"Rubin","year":"1990","journal-title":"Blood"},{"issue":"1","key":"2019111904041867400_B22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1309\/AJCPZRRL2DGC2ODA","article-title":"Myelodysplastic syndrome\/acute myeloid leukemia with t(3;21)(q26.2;q22) is commonly a therapy-related disease associated with poor outcome.","volume":"138","author":"Li","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"2019111904041867400_B23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","article-title":"A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.","volume":"25","author":"Yamazaki","year":"2014","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111904041867400_B24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.","volume":"157","author":"Gr\u00f6schel","year":"2014","journal-title":"Cell"},{"issue":"3","key":"2019111904041867400_B25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.mt.6300372","article-title":"The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy.","volume":"16","author":"M\u00e9tais","year":"2008","journal-title":"Mol Ther"},{"issue":"1","key":"2019111904041867400_B26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2014-07-591461","article-title":"Mutational spectrum of myeloid malignancies with inv(3)\/t(3;3) reveals a predominant involvement of RAS\/RTK signaling pathways.","volume":"125","author":"Gr\u00f6schel","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111904041867400_B27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cancergen.2014.05.006","article-title":"The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase inhibitors.","volume":"207","author":"Theil","year":"2014","journal-title":"Cancer Genet"},{"issue":"7","key":"2019111904041867400_B28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cancergen.2011.06.002","article-title":"Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.","volume":"204","author":"Paquette","year":"2011","journal-title":"Cancer Genet"},{"issue":"10","key":"2019111904041867400_B29","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"2019111904041867400_B30","article-title":"Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors [published online ahead of print April 14, 2015].","author":"Wang","journal-title":"Leukemia"},{"issue":"16","key":"2019111904041867400_B31","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2009-02-163485","article-title":"How I monitor residual disease in chronic myeloid leukemia.","volume":"114","author":"Radich","year":"2009","journal-title":"Blood"},{"issue":"42","key":"2019111904041867400_B32","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1038\/onc.2014.108","article-title":"Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.","volume":"33","author":"Sato","year":"2014","journal-title":"Oncogene"},{"issue":"5","key":"2019111904041867400_B33","first-page":"788","article-title":"Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia.","volume":"10","author":"Ogawa","year":"1996","journal-title":"Leukemia"},{"issue":"26","key":"2019111904041867400_B34","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1182\/blood-2010-01-264234","article-title":"EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.","volume":"116","author":"Daghistani","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111904041867400_B35","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1182\/blood-2007-10-119230","article-title":"High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.","volume":"111","author":"Lugthart","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2019111904041867400_B36","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1182\/blood-2009-07-234310","article-title":"Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.","volume":"117","author":"Arai","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111904041867400_B37","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2011-11-393827","article-title":"EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.","volume":"119","author":"Bindels","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111904041867400_B38","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.","volume":"28","author":"Gr\u00f6schel","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111904041867400_B39","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.chembiol.2014.07.019","article-title":"Targeted suppression of EVI1 oncogene expression by sequence-specific pyrrole-imidazole polyamide.","volume":"21","author":"Syed","year":"2014","journal-title":"Chem Biol"},{"issue":"1","key":"2019111904041867400_B40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-015-0128-2","article-title":"Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.","volume":"8","author":"Wang","year":"2015","journal-title":"J Hematol Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/14\/1699\/1389014\/1699.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/14\/1699\/1389014\/1699.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T10:57:08Z","timestamp":1718017028000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/126\/14\/1699\/34451\/Clinical-and-prognostic-significance-of-3q262-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,1]]},"references-count":40,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-05-646489","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,1]]}}}